Literature DB >> 18057169

Gene therapy in head and neck cancer: a review.

E Chisholm1, U Bapat, C Chisholm, G Alusi, G Vassaux.   

Abstract

Gene therapy for cancer is a rapidly evolving field with head and neck squamous cell cancer being one of the more frequently targeted cancer types. The number of clinical trials in the UK is growing and there is already a commercially available agent in China. Various gene therapy strategies along with delivery mechanisms for targeting head and neck cancer are reviewed.

Entities:  

Mesh：

Year:  2007        PMID： 18057169      PMCID： PMC2750919          DOI： 10.1136/pgmj.2007.061994

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  45 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Natural history of untreated head and neck cancer.

Authors:  L P Kowalski; A L Carvalho
Journal:  Eur J Cancer       Date:  2000-05       Impact factor: 9.162

Review 3.  Utilization of synthetic peptides containing nuclear localization signals for nonviral gene transfer systems.

Authors:  R Cartier; R Reszka
Journal:  Gene Ther       Date:  2002-02       Impact factor: 5.250

Review 4.  Cancer gene therapy: Part 2. Candidate transgenes and their clinical development.

Authors:  Kevin J Harrington; Alan A Melcher; Andrew R Bateman; Atique Ahmed; Richard G Vile
Journal:  Clin Oncol (R Coll Radiol)       Date:  2002-04       Impact factor: 4.126

Review 5.  Cancer gene therapy: hard lessons and new courses.

Authors:  R G Vile; S J Russell; N R Lemoine
Journal:  Gene Ther       Date:  2000-01       Impact factor: 5.250

6.  A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer.

Authors:  I Ganly; D Kirn; G Eckhardt; G I Rodriguez; D S Soutar; R Otto; A G Robertson; O Park; M L Gulley; C Heise; D D Von Hoff; S B Kaye; S G Eckhardt
Journal:  Clin Cancer Res       Date:  2000-03       Impact factor: 12.531

7.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.

Authors:  M Cavazzana-Calvo; S Hacein-Bey; G de Saint Basile; F Gross; E Yvon; P Nusbaum; F Selz; C Hue; S Certain; J L Casanova; P Bousso; F L Deist; A Fischer
Journal:  Science       Date:  2000-04-28       Impact factor: 47.728

8.  Clinical usefulness of telomerase activation and telomere length in head and neck cancer.

Authors:  Mintoo M Patel; Lalit J Parekh; Franky P Jha; Rachana N Sainger; Jayendra B Patel; Devendra D Patel; Pankaj M Shah; Prabhudas S Patel
Journal:  Head Neck       Date:  2002-12       Impact factor: 3.147

9.  [Effectiveness of recombinant adenovirus p53 injection on laryngeal cancer: phase I clinical trial and follow up].

Authors:  De-min Han; Zhi-gang Huang; Wei Zhang; Zhen-kun Yu; Qi Wang; Xin Ni; Xiao-hong Chen; Jin-hua Pan; Hong Wang
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2003-12-10

10.  Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene.

Authors:  Thomas Groot-Wassink; Eric O Aboagye; Matthias Glaser; Nicholas R Lemoine; Georges Vassaux
Journal:  Hum Gene Ther       Date:  2002-09-20       Impact factor: 5.695
View more
  3 in total

Review 1.  Intratumoral generation of 2-fluoroadenine to treat solid malignancies of the head and neck.

Authors:  Turang E Behbahani; Eben L Rosenthal; William B Parker; Eric J Sorscher
Journal:  Head Neck       Date:  2019-01-11       Impact factor: 3.147

2.  Gene therapy.

Authors:  B J Baum
Journal:  Oral Dis       Date:  2013-12-26       Impact factor: 3.511

Review 3.  Gene Therapy: A Paradigm Shift in Dentistry.

Authors:  Nida Siddique; Hira Raza; Sehrish Ahmed; Zohaib Khurshid; Muhammad Sohail Zafar
Journal:  Genes (Basel)       Date:  2016-11-10       Impact factor: 4.096
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.